{"product_id":"twistbioscience-swot-analysis","title":"Twist Bioscience SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTwist Bioscience is a leader in DNA synthesis, boasting strong technological innovation and a growing market presence. However, understanding the competitive landscape and potential regulatory hurdles is crucial for navigating its future. \u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind Twist Bioscience's market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways—ideal for entrepreneurs, analysts, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Silicon Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's proprietary silicon-based DNA synthesis platform is a major strength. This technology allows for the efficient, high-volume production of synthetic DNA, setting them apart from competitors using older methods. It's the backbone of their ability to offer a wide range of DNA products.\u003c\/p\u003e\n\u003cp\u003eThis innovative platform not only delivers high-quality DNA but also does so at a more cost-effective rate. For instance, in Q1 2024, Twist Bioscience reported a 13% increase in DNA synthesis revenue year-over-year, demonstrating the market's demand for their efficient production capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Portfolio and Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience boasts a diverse product portfolio, encompassing synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries. This breadth of offerings allows the company to serve a wide array of industries, including pharmaceuticals, diagnostics, agriculture, and technology.\u003c\/p\u003e\n\u003cp\u003eThis diversification is a significant strength, as it reduces the company's dependence on any single market segment. For instance, in fiscal year 2023, Twist Bioscience reported revenue growth across multiple segments, demonstrating the broad applicability of its synthetic DNA solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience is experiencing impressive revenue expansion. For the second quarter of fiscal year 2025, the company reported a significant 23% increase in revenue compared to the same period in the previous year, achieving $92.8 million. This upward trend highlights strong market reception and increasing adoption of their synthetic biology solutions.\u003c\/p\u003e\n\u003cp\u003eThe company's ability to deliver consistent sequential growth further solidifies its financial health. Management's decision to raise the full-year fiscal 2025 revenue guidance underscores confidence in sustained demand. This positive outlook is driven by robust performance across key business segments, including Synthetic Biology, Next-Generation Sequencing (NGS), and Biopharma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproving Gross Margins and Operational Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience has demonstrated a strong upward trend in its gross margins, a key indicator of its improving operational health. In the second quarter of fiscal year 2025, the company achieved a gross margin of 49.6%, a notable increase from 41% in the same period of fiscal year 2024. This advancement highlights the positive impact of management's strategic focus on enhancing operational efficiencies. \u003c\/p\u003e\n\u003cp\u003eThe company's commitment to automation and rigorous cost-cutting initiatives is directly contributing to this margin expansion. Twist Bioscience has set an ambitious target to surpass 50% gross margin by the fourth quarter of fiscal year 2025. This forward-looking goal underscores the company's progress toward greater profitability and financial sustainability, reflecting effective execution of its business strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGross Margin Improvement:\u003c\/strong\u003e Reached 49.6% in Q2 FY2025, up from 41% in Q2 FY2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Efficiency:\u003c\/strong\u003e Driven by automation and cost reduction efforts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProfitability Target:\u003c\/strong\u003e Aiming to exceed 50% gross margin by Q4 FY2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience’s strategic collaborations are a significant strength, allowing them to tap into new markets and accelerate innovation. Their partnership with Element Biosciences, for instance, aims to streamline next-generation sequencing (NGS) workflows, a critical area for genomic research and diagnostics. This kind of alliance helps integrate Twist’s synthetic biology tools with complementary technologies.\u003c\/p\u003e\n\u003cp\u003eFurther bolstering this strength is their collaboration with Absci, focusing on the use of generative AI for antibody design. This partnership is at the forefront of drug discovery, leveraging advanced computational methods to create novel therapeutic candidates. Such ventures not only enhance Twist’s technological capabilities but also position them as a key enabler in the rapidly evolving biopharmaceutical landscape.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances are crucial for expanding market reach and enhancing product offerings. By teaming up with industry leaders, Twist Bioscience can access broader customer bases and integrate their synthetic DNA solutions into more comprehensive platforms. This collaborative approach is vital for driving adoption and demonstrating the value of their core technology in diverse applications.\u003c\/p\u003e\n\u003cp\u003eKey aspects of these collaborations include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e Partnerships provide access to new customer segments and geographical regions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccelerated Innovation:\u003c\/strong\u003e Joint development efforts speed up the creation and refinement of new products and services.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Offerings:\u003c\/strong\u003e Integration with partners' technologies creates more complete and valuable solutions for customers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndustry Validation:\u003c\/strong\u003e Collaborations with established players lend credibility and market acceptance to Twist Bioscience's offerings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Tech Powers Revenue Surge and Margin Gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's proprietary silicon-based DNA synthesis platform is a significant strength, enabling efficient, high-volume production of synthetic DNA. This advanced technology underpins their ability to offer a wide range of DNA products at a more cost-effective rate, as evidenced by a 13% year-over-year increase in DNA synthesis revenue in Q1 2024.\u003c\/p\u003e\n\u003cp\u003eThe company's diverse product portfolio, including synthetic genes and NGS tools, reduces reliance on single market segments, as demonstrated by revenue growth across multiple segments in fiscal year 2023. Furthermore, Twist Bioscience is experiencing impressive revenue expansion, with a 23% increase in Q2 FY2025 revenue to $92.8 million, and has raised its full-year FY2025 revenue guidance due to strong performance across key business areas.\u003c\/p\u003e\n\u003cp\u003eA key financial strength is the company's improving gross margins, reaching 49.6% in Q2 FY2025, up from 41% in Q2 FY2024, driven by automation and cost-cutting. Twist Bioscience aims to surpass 50% gross margin by Q4 FY2025, signaling enhanced profitability and operational efficiency.\u003c\/p\u003e\n\u003cp\u003eStrategic collaborations, such as with Element Biosciences for NGS workflows and Absci for AI-driven antibody design, are crucial for market expansion and accelerated innovation, integrating Twist’s synthetic biology tools into broader technological ecosystems.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 FY2024\u003c\/th\u003e\n\u003cth\u003eQ2 FY2025\u003c\/th\u003e\n\u003cth\u003eChange\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$75.4 million\u003c\/td\u003e\n\u003ctd\u003e$92.8 million\u003c\/td\u003e\n\u003ctd\u003e+23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e41.0%\u003c\/td\u003e\n\u003ctd\u003e49.6%\u003c\/td\u003e\n\u003ctd\u003e+8.6 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis maps Twist Bioscience's internal capabilities, such as its proprietary silicon-based DNA synthesis platform, against external market opportunities in synthetic biology and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable framework to address Twist Bioscience's market challenges and leverage its technological strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Net Losses and Path to Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience has consistently shown robust revenue growth and expanding gross margins, a positive sign for its core business. However, the company continues to grapple with persistent net losses, reporting a net loss of $0.66 per share in the second quarter of fiscal year 2025. This ongoing profitability challenge necessitates careful scrutiny of its cash burn rate and the effectiveness of its strategies to achieve financial sustainability.\u003c\/p\u003e\n\u003cp\u003eWhile management is targeting adjusted EBITDA breakeven by the close of fiscal year 2026, the sustained net losses raise valid concerns regarding the company's long-term profitability trajectory. Investors and stakeholders will be closely monitoring the company's ability to manage its expenses and convert its top-line growth into bottom-line positive results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operating Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience faces a significant challenge with its high operating expenses. These costs are driven by substantial investments in research and development, crucial for innovation in the synthetic biology space, and ongoing expansions of its manufacturing infrastructure. \u003c\/p\u003e\n\u003cp\u003eFor instance, in the second quarter of fiscal year 2025, the company reported operating expenses reaching $47.3 million. This figure underscores the ongoing need for stringent cost management and strategic resource allocation to ensure these expenditures contribute effectively to achieving the company's long-term financial objectives and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Macroeconomic Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's revenue streams are closely tied to the health of the biotechnology and pharmaceutical sectors, making them vulnerable to macroeconomic headwinds. For instance, a significant economic slowdown in 2024 or 2025 could lead to reduced R\u0026amp;D budgets across these industries, directly impacting demand for Twist's synthetic DNA products and services.  This sensitivity means that market downturns can translate into lower sales volumes and potentially slower growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition in a Rapidly Evolving Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe synthetic biology and genomics market is incredibly dynamic, with new technologies emerging at a rapid pace. This intense competition means Twist Bioscience must constantly innovate and be mindful of its pricing to stay ahead.  Failure to do so risks falling behind established players and nimble startups, potentially leading to product obsolescence.\u003c\/p\u003e\n\u003cp\u003eTwist Bioscience operates in a sector where technological advancements can quickly shift the competitive landscape.  For instance, advancements in gene editing and DNA synthesis platforms by competitors could challenge Twist's current market position.  The company's ability to adapt its offerings and maintain cost-effectiveness is crucial for sustained growth in this evolving market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntense Competition:\u003c\/strong\u003e The synthetic biology market is crowded with both large, established biotech firms and numerous agile startups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRapid Technological Change:\u003c\/strong\u003e Continuous innovation in areas like CRISPR, AI-driven gene design, and novel DNA synthesis methods creates constant pressure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Pressures:\u003c\/strong\u003e Competitors' pricing strategies can impact Twist's market share and profitability, necessitating efficient operations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk of Obsolescence:\u003c\/strong\u003e Without ongoing R\u0026amp;D and product development, Twist's offerings could become outdated as new technologies emerge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on External Funding for Growth Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience's ambitious growth plans, particularly in areas like DNA data storage, necessitate significant capital infusion. While the company maintains a healthy cash position, these long-term, capital-intensive projects may outstrip internal resources. For instance, the spin-out of Atlas Data Storage, which secured substantial external funding, underscores the reliance on outside investment for such ventures.\u003c\/p\u003e\n\u003cp\u003eThis dependence on external funding presents a potential weakness:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapital Intensity:\u003c\/strong\u003e Growth initiatives, especially in emerging fields like DNA data storage, require considerable upfront investment that may exceed internally generated cash flows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancing Risk:\u003c\/strong\u003e The need for external capital exposes Twist Bioscience to market conditions and investor sentiment, potentially impacting the timing and scale of growth projects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDilution Concerns:\u003c\/strong\u003e Future equity financing to fund these initiatives could lead to shareholder dilution, affecting per-share metrics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNavigating Biotech Headwinds: Financial Pressures and Growth Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's reliance on the biotech and pharma sectors makes it susceptible to economic downturns, potentially impacting R\u0026amp;D spending and thus demand for its products. For example, a slowdown in 2024 or 2025 could directly reduce sales. The company also faces intense competition and rapid technological shifts, requiring continuous innovation and cost management to avoid product obsolescence.\u003c\/p\u003e\n\u003cp\u003eThe company's high operating expenses, driven by R\u0026amp;D and manufacturing expansion, contribute to ongoing net losses. In Q2 FY2025, operating expenses were $47.3 million, highlighting the need for effective cost control to achieve profitability. While management aims for adjusted EBITDA breakeven by fiscal year 2026, sustained net losses remain a concern.\u003c\/p\u003e\n\u003cp\u003eGrowth initiatives, particularly in capital-intensive areas like DNA data storage, necessitate significant external funding. This reliance on outside investment introduces financing risks and potential shareholder dilution. The spin-out of Atlas Data Storage, which required substantial external funding, illustrates this dependence.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eTwist Bioscience SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real document you'll receive—professional, structured, and ready to use. You're seeing the actual Twist Bioscience SWOT analysis, providing a clear understanding of its strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003cp\u003eThe content below is pulled directly from the final SWOT analysis. Unlock the full report when you purchase to gain a comprehensive understanding of Twist Bioscience's strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Synthetic Biology and DNA Synthesis Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global DNA synthesis market is on a significant upward trajectory, projected to reach USD 16.08 billion by 2032, up from USD 4.56 billion in 2024. This robust growth, with an anticipated compound annual growth rate of 17.5%, is fueled by innovations in personalized medicine and gene therapies.\u003c\/p\u003e\n\u003cp\u003eThis expanding market presents a prime opportunity for Twist Bioscience to solidify and grow its position. By leveraging its advanced synthesis capabilities, the company can capture a larger share of this burgeoning market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Personalized Medicine and Gene Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe burgeoning field of personalized medicine and gene therapies presents a significant opportunity.  Demand for treatments tailored to individual genetic profiles, especially in oncology and rare diseases, is escalating.  This trend directly fuels the need for synthetic DNA, a core offering from companies like Twist Bioscience.\u003c\/p\u003e\n\u003cp\u003eSynthetic DNA is indispensable for creating precise diagnostics, identifying biomarkers, and developing novel therapeutic approaches for these specialized treatments.  Twist Bioscience's expertise in DNA synthesis positions them advantageously to capitalize on this growing market.  For instance, the global gene therapy market was valued at approximately $10.9 billion in 2023 and is projected to reach $35.1 billion by 2030, demonstrating substantial growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancements in DNA Data Storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience is at the forefront of DNA data storage, a groundbreaking technology. The company's spin-out of Atlas Data Storage is a strategic move to accelerate the commercialization of this innovative solution. This emerging field promises incredibly dense and durable data storage, far surpassing current magnetic or optical methods.\u003c\/p\u003e\n\u003cp\u003eThe potential for DNA data storage to become a major revenue source is significant. Twist Bioscience stands to benefit through development milestones and ongoing royalties as the technology matures and gains market traction. Experts project the data storage market to reach hundreds of billions of dollars by the end of the decade, with DNA storage poised to capture a substantial share as it becomes more cost-effective and accessible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreasing Adoption of Next-Generation Sequencing (NGS) Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe market for next-generation sequencing (NGS) is experiencing robust expansion, driven by its critical roles in areas like liquid biopsies for cancer detection, diagnosing rare genetic diseases, and a wide array of research and clinical diagnostic applications.  This growing demand presents a significant opportunity for companies like Twist Bioscience.  Indeed, the global NGS market was valued at approximately $12.2 billion in 2023 and is projected to reach over $30 billion by 2028, showcasing a compound annual growth rate (CAGR) of around 20%.\u003c\/p\u003e\n\u003cp\u003eTwist Bioscience's comprehensive suite of NGS tools, including their DNA synthesis platforms and library preparation kits, are well-positioned to benefit from this market surge. Their strategic partnerships within the diagnostics and research sectors further enhance their ability to capture market share as the adoption of advanced sequencing technologies continues to accelerate.  For instance, their collaboration with Illumina, a major player in sequencing hardware, directly addresses the growing need for efficient and high-quality reagents in the NGS workflow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowing NGS Market:\u003c\/strong\u003e The global NGS market is expanding rapidly, with projections indicating continued strong growth through 2028.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Application Drivers:\u003c\/strong\u003e Increased use in liquid biopsy, rare disease diagnostics, and broader research applications fuels demand for NGS solutions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTwist Bioscience's Position:\u003c\/strong\u003e The company's advanced DNA synthesis and library preparation tools align perfectly with the increasing adoption of NGS technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePartnership Advantage:\u003c\/strong\u003e Strategic alliances, such as with Illumina, bolster Twist Bioscience's ability to serve the expanding NGS ecosystem.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion into Emerging Markets and Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience has a significant opportunity to broaden its reach by expanding into emerging markets, with regions like Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) demonstrating robust growth potential.  For instance, the EMEA life sciences market is projected to reach over $200 billion by 2025, presenting a substantial runway for Twist's DNA synthesis services.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the company can unlock new revenue streams and customer segments by applying its synthetic DNA technology to diverse fields. These include developing sustainable industrial chemicals, enhancing agricultural yields through advanced crop science, and bolstering national defense capabilities with novel biological solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Footprint Expansion:\u003c\/strong\u003e Targeting high-growth regions like EMEA and APAC, which are experiencing increasing investment in biotechnology and life sciences research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNew Application Avenues:\u003c\/strong\u003e Diversifying revenue by exploring synthetic DNA applications in sectors such as industrial biotechnology, agriculture, and defense.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Penetration:\u003c\/strong\u003e Leveraging existing partnerships and establishing new ones to gain traction in these expanding geographical and industry segments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlocking Billions: DNA Synthesis \u0026amp; Data Storage Drive Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global DNA synthesis market is projected to reach USD 16.08 billion by 2032, growing at a 17.5% CAGR, presenting a significant opportunity for Twist Bioscience to expand its market share in personalized medicine and gene therapies.\u003c\/p\u003e\n\u003cp\u003eTwist Bioscience's strategic spin-out of Atlas Data Storage positions it to capitalize on the emerging DNA data storage market, which could represent a substantial future revenue stream as the technology matures and becomes more accessible, potentially reaching hundreds of billions of dollars.\u003c\/p\u003e\n\u003cp\u003eThe expanding Next-Generation Sequencing (NGS) market, valued at approximately $12.2 billion in 2023 and expected to exceed $30 billion by 2028, offers a strong opportunity for Twist Bioscience's synthesis and library preparation tools, further bolstered by strategic collaborations.\u003c\/p\u003e\n\u003cp\u003eExpanding into emerging markets like EMEA and APAC, with the EMEA life sciences market projected to exceed $200 billion by 2025, and diversifying into industrial biotechnology, agriculture, and defense applications, provides additional avenues for growth and new revenue streams.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition and Pricing Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience faces a significant threat from intense competition. The synthetic biology market is attracting numerous players, from established life science companies to agile startups, all vying for market share. This crowded field inevitably leads to pricing pressures, potentially impacting Twist Bioscience's ability to command premium pricing for its DNA synthesis services.\u003c\/p\u003e\n\u003cp\u003eThe competitive landscape directly translates into pricing pressures, a critical concern for Twist Bioscience. As more companies offer similar services, the incentive to lower prices to attract customers increases. For instance, in 2023, the synthetic biology market was valued at approximately $12.5 billion, with projections indicating substantial growth, further fueling competitive entry and price sensitivity. This could erode gross margins and make it harder for Twist Bioscience to achieve its profitability targets.\u003c\/p\u003e\n\u003cp\u003eMaintaining and expanding market share becomes an uphill battle under such competitive conditions. Twist Bioscience must continually innovate and differentiate its offerings to stand out. Failure to do so could see customers opting for lower-cost alternatives, even if they offer slightly less advanced technology or slower turnaround times. This dynamic underscores the constant need for strategic pricing and service enhancements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Ethical Challenges in Synthetic Biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe synthetic biology sector, including companies like Twist Bioscience, faces a dynamic landscape of regulatory scrutiny, particularly around gene editing technologies and genetically modified organisms (GMOs).  As of early 2024, discussions around updating frameworks like the National Environmental Policy Act (NEPA) in the US continue, potentially impacting the approval pathways for new bio-engineered products.\u003c\/p\u003e\n\u003cp\u003eShifts in these regulations, or even public sentiment regarding the safety and ethics of synthetic biology applications, can significantly influence product development timelines and market adoption.  For instance, differing international approaches to GMO labeling and approval create complexity for global commercialization efforts.\u003c\/p\u003e\n\u003cp\u003eEthical debates surrounding germline editing and the responsible use of powerful genetic tools add another layer of challenge.  Companies must navigate these evolving ethical considerations alongside regulatory hurdles to ensure long-term market acceptance and avoid potential backlash that could hinder growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Disruptions and Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal supply chain vulnerabilities, exacerbated by geopolitical events and logistical challenges, pose a significant threat to Twist Bioscience.  In 2024, the cost of key raw materials, such as nucleotides and reagents, saw an average increase of 8-12% due to these pressures, directly impacting production costs.  A disruption in the availability of these essential components could hinder their ability to meet demand and affect profit margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Infringement and Litigation Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience's reliance on its proprietary DNA synthesis platform exposes it to the significant threat of intellectual property infringement and litigation. Competitors or other entities could allege that Twist's technology infringes on existing patents, leading to costly legal battles and potential injunctions that disrupt operations. \u003c\/p\u003e\n\u003cp\u003eThe company also faces the risk of its own patents being challenged and invalidated, which could erode its competitive edge in the synthetic biology market. For instance, in the rapidly evolving biotech landscape, patent disputes are common, and a loss in such a case could allow rivals to replicate Twist's core technologies, impacting its market share and revenue streams. \u003c\/p\u003e\n\u003cp\u003eAs of late 2023 and early 2024, the synthetic biology sector continues to see increased patent filings and potential for disputes, making robust IP protection a critical operational concern for Twist Bioscience. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlow Adoption of Cutting-Edge Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe life sciences sector, while innovative, can exhibit a cautious approach to adopting new technologies. This means that even groundbreaking solutions from companies like Twist Bioscience might face a slower uptake than anticipated.  For instance, in 2024, many biotech firms were still evaluating the ROI and integration challenges of advanced gene synthesis platforms, impacting the speed at which new players could gain widespread market penetration.\u003c\/p\u003e\n\u003cp\u003eThis slower adoption rate, coupled with a potentially niche market for highly specialized synthetic biology applications, presents a significant hurdle.  The addressable market for certain advanced DNA synthesis services might be limited initially, affecting the scalability of Twist Bioscience's growth trajectory.  By the end of 2024, reports indicated that while demand for gene synthesis was robust, the adoption of truly novel applications was still in its nascent stages across many research institutions and pharmaceutical companies.\u003c\/p\u003e\n\u003cp\u003eA key factor contributing to this threat is the inherent complexity and regulatory environment within life sciences. Implementing cutting-edge technologies often requires extensive validation, integration with existing workflows, and navigating stringent compliance standards. This can create a longer sales cycle and delay revenue generation, a challenge observed in early 2025 as companies assessed the long-term viability and integration costs of advanced genomic tools.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynthetic Biology: The Race Against Obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe threat of technological obsolescence looms large for Twist Bioscience. As the synthetic biology field advances rapidly, newer, more efficient DNA synthesis methods could emerge, rendering current platforms less competitive. For example, advancements in enzymatic DNA synthesis, which promise higher accuracy and lower costs, are actively being researched and could pose a challenge by 2025.\u003c\/p\u003e\n\u003cp\u003eThe company's reliance on its proprietary technology also makes it vulnerable to disruptive innovations from competitors. If another company develops a significantly superior or more cost-effective DNA synthesis method, Twist Bioscience could lose its technological edge. This necessitates continuous investment in research and development to stay ahead of the curve, a costly endeavor in a fast-paced scientific landscape.\u003c\/p\u003e\n\u003cp\u003eFurthermore, shifts in research priorities or the emergence of entirely new biological engineering paradigms could reduce the demand for current DNA synthesis services. For instance, a breakthrough in direct RNA synthesis or novel methods for gene assembly might alter the market's focus, impacting Twist Bioscience's core business. By late 2024, early indicators suggested a growing interest in cell-free protein synthesis systems, potentially diverting some research funding from traditional DNA synthesis needs.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eSWOT Analysis \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThis SWOT analysis is built upon a foundation of robust data, drawing from Twist Bioscience's official financial filings, comprehensive market research reports, and insights from industry experts. These sources collectively provide a well-rounded view of the company's strategic landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098466685276,"sku":"twistbioscience-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/twistbioscience-swot-analysis.png?v=1781808501","url":"https:\/\/pestel-analysis.com\/products\/twistbioscience-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}